Business Context and Reporting Period
Company: Radiopharm Theranostics Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of August 2025
Date of Filing: August 29, 2025
Context: The filing serves to transmit a Public Notice published to the Australian Securities Exchange (ASX) titled "Appendix 4E and Preliminary Final Report."
Key Financial Metrics
The provided Form 6-K text acts as a cover document and does not contain specific financial data. The actual financial figures (revenue, profit, cash flow, margins, debt, and liquidity) are contained within the attached Exhibit 99.1 ("Appendix 4E and Preliminary Final Report"), which is not included in the input text. Therefore, no specific values can be reported from this document alone.
Material Changes
The filing text does not provide details on material changes versus prior periods. Such information is expected to be detailed in the attached Preliminary Final Report (Exhibit 99.1).
Guidance, Outlook, and Risks
The text does not contain management commentary, guidance, outlook, or specific risk factors. The filing explicitly states that the report and its exhibits shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings unless expressly set forth.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Appendix 4E and Preliminary Final Report) for actual financial results and operational updates.
- Verify the company's compliance with ASX listing rules regarding the Appendix 4E disclosure.
- Confirm the status of the "Preliminary Final Report" to understand the proposed dividend or capital return details, if any.
- Note that this Form 6-K is a notification of the ASX announcement and does not constitute a standalone financial report.